893 related articles for article (PubMed ID: 24589424)
1. Challenges to pharmaceutical policymaking: lessons from Australia's national medicines policy.
Lipworth W; Doran E; Kerridge I; Day R
Aust Health Rev; 2014 May; 38(2):160-8. PubMed ID: 24589424
[TBL] [Abstract][Full Text] [Related]
2. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
Morgan S; McMahon M; Greyson D
Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
[TBL] [Abstract][Full Text] [Related]
3. Developing a national medicines information strategy in Finland--a stakeholders' perspective on the strengths, challenges and opportunities in medicines information.
Hämeen-Anttila K; Luhtanen S; Airaksinen M; Pohjanoksa-Mäntylä M
Health Policy; 2013 Jul; 111(2):200-5. PubMed ID: 23683473
[TBL] [Abstract][Full Text] [Related]
4. A perspective on Australia's National Medicines Policy.
Tett SE
Can J Clin Pharmacol; 2004; 11(1):e28-38. PubMed ID: 15226524
[TBL] [Abstract][Full Text] [Related]
5. Eliciting views of Australian pharmaceutical industry employees on collaboration and the concept of Quality Use of Medicines.
Wang N; Lipworth WL; Ritchie JE; Williams KM; Day RO
Intern Med J; 2011 Apr; 41(4):314-20. PubMed ID: 20403068
[TBL] [Abstract][Full Text] [Related]
6. Drug quality in South Africa: perceptions of key players involved in medicines distribution.
Patel A; Norris P; Gauld R; Rades T
Int J Health Care Qual Assur; 2009; 22(5):547-60. PubMed ID: 19725374
[TBL] [Abstract][Full Text] [Related]
7. Implementing and using quality measures for children's health care: perspectives on the state of the practice.
Shaller D
Pediatrics; 2004 Jan; 113(1 Pt 2):217-27. PubMed ID: 14702504
[TBL] [Abstract][Full Text] [Related]
8. Align, share responsibility and collaborate: potential considerations to aid in e-health policy development.
Ragaban N; Day K; Orr M
Stud Health Technol Inform; 2012; 178():186-91. PubMed ID: 22797040
[TBL] [Abstract][Full Text] [Related]
9. Developing an equivalent to the National Medicines Policy for medical devices.
Smith MW; Faunce TA
J Law Med; 2009 Dec; 17(3):412-25. PubMed ID: 20169801
[TBL] [Abstract][Full Text] [Related]
10. Essential Medicines in a High Income Country: Essential to Whom?
Duong M; Moles RJ; Chaar B; Chen TF;
PLoS One; 2015; 10(12):e0143654. PubMed ID: 26650544
[TBL] [Abstract][Full Text] [Related]
11. Perception of prescription medicine sample packs among Australian professional, government, industry, and consumer organizations, based on automated textual analysis of one-on-one interviews.
Kyle GJ; Nissen L; Tett S
Clin Ther; 2008 Dec; 30(12):2461-73. PubMed ID: 19167604
[TBL] [Abstract][Full Text] [Related]
12. Striving for quality use of medicines: how effective is Australia's ban on direct-to-consumer prescription medicine advertising?
Brown S
J Law Med; 2009 Feb; 16(4):666-83. PubMed ID: 19297873
[TBL] [Abstract][Full Text] [Related]
13. Evaluating Australia's National Medicines Policy using geographical mapping.
Roughead EE; Monteith GR; Harvey KJ; Tett SE
Intern Med J; 2002 Mar; 32(3):66-71. PubMed ID: 11885845
[TBL] [Abstract][Full Text] [Related]
14. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
[TBL] [Abstract][Full Text] [Related]
15. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
16. Chronic conditions, financial burden and pharmaceutical pricing: insights from Australian consumers.
Whitty JA; Sav A; Kelly F; King MA; McMillan SS; Kendall E; Wheeler AJ
Aust Health Rev; 2014 Nov; 38(5):589-95. PubMed ID: 25099307
[TBL] [Abstract][Full Text] [Related]
17. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
[TBL] [Abstract][Full Text] [Related]
18. Exploring policy-makers' perspectives on disinvestment from ineffective healthcare practices.
Elshaug AG; Hiller JE; Moss JR
Int J Technol Assess Health Care; 2008; 24(1):1-9. PubMed ID: 18218163
[TBL] [Abstract][Full Text] [Related]
19. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
Mansfield SJ
Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
[TBL] [Abstract][Full Text] [Related]
20. Perspectives on Drug and Therapeutics Committee policy implementation.
Tan EL; Day RO; Brien JA
Res Social Adm Pharm; 2005 Dec; 1(4):526-45. PubMed ID: 17138494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
